Trexquant Investment LP grew its stake in Inogen, Inc. (NASDAQ:INGN - Free Report) by 137.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 125,930 shares of the medical technology company's stock after buying an additional 72,871 shares during the period. Trexquant Investment LP owned 0.53% of Inogen worth $1,155,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also made changes to their positions in the stock. AlphaQuest LLC purchased a new position in Inogen in the 4th quarter worth $43,000. Meeder Asset Management Inc. purchased a new position in shares of Inogen in the fourth quarter worth about $56,000. Ieq Capital LLC purchased a new position in shares of Inogen in the fourth quarter worth about $94,000. Intech Investment Management LLC acquired a new stake in shares of Inogen during the fourth quarter worth about $94,000. Finally, Verition Fund Management LLC purchased a new stake in Inogen in the third quarter valued at approximately $106,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research firms have issued reports on INGN. Needham & Company LLC reissued a "hold" rating on shares of Inogen in a research report on Wednesday, April 9th. StockNews.com cut shares of Inogen from a "buy" rating to a "hold" rating in a report on Wednesday, February 26th.
Read Our Latest Stock Analysis on INGN
Inogen Stock Down 1.6 %
Shares of INGN traded down $0.12 during mid-day trading on Tuesday, reaching $7.20. The company had a trading volume of 82,218 shares, compared to its average volume of 240,283. The stock has a market capitalization of $193.59 million, a P/E ratio of -3.20 and a beta of 1.48. Inogen, Inc. has a 52-week low of $6.40 and a 52-week high of $13.33. The stock has a 50 day moving average of $8.24 and a two-hundred day moving average of $9.21.
Inogen Company Profile
(
Free Report)
Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
Further Reading
Before you consider Inogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inogen wasn't on the list.
While Inogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
